FDA Proposes New Rules for Tobacco Product Manufacturing

Mar.09.2023
FDA Proposes New Rules for Tobacco Product Manufacturing
The FDA proposes new rules for tobacco product manufacturing to protect public health and ensure consistency and reduce contamination.

US regulatory agency will seek input from advisory committees and the general public regarding proposed regulations.


The United States Food and Drug Administration (FDA) has proposed new requirements for the manufacturing, design, packaging, and storage of electronic cigarettes and other tobacco products. The proposed regulations aim to protect public health, minimize or prevent contamination, limit additional risks, and ensure product consistency.


The proposed regulations apply to manufacturers of both finished and bulk electronic cigarettes and other tobacco products. Under the proposed rules, finished tobacco products refer to any component or part of a tobacco product that is packaged in the final packaging, such as electronic cigarettes, cigarette packaging, or wet tobacco cans. Bulk tobacco products refer to tobacco products that are not packaged in the final packaging but are suitable for consumer use.


This proposed new regulation will be beneficial for manufacturers.


Adhere to the Federal Food, Drug and Cosmetic Act and take measures to minimize or prevent contamination in tobacco products, such as metals, glass, and plastics.


Solution to the problem of inconsistency between electronic cigarette e-liquid product labels and actual concentration.


3. Establish requirements related to identification, traceability, and correction of tobacco products that do not meet specifications or have been contaminated, including those already distributed.


If issues arise, these regulations will require manufacturers to take corrective action, which might include initiating a recall.


The proposed rules establish a framework for manufacturers to comply with, which includes:


Establish a mechanism for controlling the design and development of tobacco products.


B. Ensure that the production of finished and loose tobacco products meets established standards.


C. Aim to minimize the production and distribution of tobacco products that do not meet industry standards.


D. It is demanded that manufacturers must take appropriate measures to prevent contamination of tobacco products.


Demanding an investigation and identification of non-compliant products in order to take appropriate corrective measures such as recalling them.


Establish the ability to track all components, parts, ingredients, additives, and materials, as well as each batch of finished or loose tobacco products, in order to assist in investigating those products that do not meet the specifications.


The FDA will hold a public hearing on April 12 to collect opinions from various stakeholders, including the industry, scientific community, advocacy groups, and the public. The proposed rules will also be open for public comment for 180 days. The FDA will review all comments.


The FDA will convene a meeting of the Tobacco Products Scientific Advisory Committee (TPSAC) on May 18 to seek recommendations from external expert groups. As part of the TPSAC meeting, the public will have an opportunity to provide verbal statements. The FDA intends to publish TPSAC meeting materials on its website no later than 48 hours before the meeting begins.


2FIRSTS will conduct interviews with individuals affected by the new regulations and continue to report on the matter.


Reference:


The U.S. Food and Drug Administration (FDA) has put forward new regulations for the manufacturing of vaping products.


The Food and Drug Administration (FDA) has put forth new regulations regarding the production practices of tobacco products. These requirements aim to improve the manufacturing standards of tobacco products in order to reduce their harmful effects on consumers.


The Proposed Rule titled "Requirements for Tobacco Product Manufacturing Practice" has been introduced.


The Tobacco Products Scientific Advisory Committee (TPSAC) convened for a meeting.


Public hearing to discuss proposed regulations for tobacco product manufacturing practices.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

UK Vaping Products Duty to Raise £565 Million by 2030/31
UK Vaping Products Duty to Raise £565 Million by 2030/31
The UK will introduce Vaping Products Duty on all vaping liquids from October 1, 2026, with government revenue forecast to rise from £135 million in 2026/27 to £565 million by 2030/31.
Jun.18
AP Questions FDA Rationale as Glas Fruit-Flavored Vapes Won Authorization Without Added Cessation Benefit
AP Questions FDA Rationale as Glas Fruit-Flavored Vapes Won Authorization Without Added Cessation Benefit
The U.S. Food and Drug Administration (FDA) recently authorized two fruit-flavored vaping products from Glas, but a newly released agency memo shows the products did not demonstrate greater smoking-cessation benefits than tobacco-flavored e-cigarettes. The Associated Press said the findings are likely to raise further questions about the FDA’s regulatory rationale and standards for flavored vaping products.
Jun.12
Product | APUS Launches Chloe 50K, Bringing Purse-Inspired Design to the U.S. High-Puff Disposable Market
Product | APUS Launches Chloe 50K, Bringing Purse-Inspired Design to the U.S. High-Puff Disposable Market
APUS has introduced the Chloe 50K disposable vape, which has appeared across U.S.-facing online retail channels including Element Vape and Vapesourcing. The device combines a purse-inspired body and chain attachment with a 20ml e-liquid capacity, 1,250mAh rechargeable battery, dual mesh coil, and battery and e-liquid indicators. It is rated for up to 50,000 puffs. The product does not appear on the FDA’s current list of authorized e-cigarettes, and U.S. retail availability does not indicate FDA marketing authorization.
Jul.15
Bringing Tax and Insurance Into Nicotine Regulation: Insights From a Tobacco Harm-Reduction Report
Bringing Tax and Insurance Into Nicotine Regulation: Insights From a Tobacco Harm-Reduction Report
A smoke-free nicotine policy report argues that tobacco harm reduction should move beyond product bans and health warnings into tax policy, insurance pricing and risk-based regulation. While some projections remain open to debate, the report highlights a wider challenge: nicotine products, technologies and consumer behavior have changed sharply over the past decade, and regulatory systems may need new tools to better align tobacco control with harm-reduction goals.
Jun.08
Illegal Vape Sellers Still Use TikTok and Other Platforms to Drive Sales Despite Australia’s Ad Ban
Illegal Vape Sellers Still Use TikTok and Other Platforms to Drive Sales Despite Australia’s Ad Ban
Illegal vape sellers are still promoting nicotine products on TikTok, Instagram and YouTube despite Australia’s 2024 advertising ban, while illicit tobacco sales are increasingly moving from physical stores to online marketplaces.
Jul.15
Australia’s Daily Smoking Rate Falls to Record Low of 5.8% as Nicotine Use Patterns Shift
Australia’s Daily Smoking Rate Falls to Record Low of 5.8% as Nicotine Use Patterns Shift
According to the Australian Institute of Health and Welfare’s National Drug Strategy Household Survey, daily smoking among Australians aged 18 and over fell to a record low of 5.8% in 2025. Health Minister Mark Butler said Australia now has around 500,000 fewer daily smokers than three years ago and credited the government’s vaping reforms as part of broader progress. Among people aged 14 and over, daily smoking declined from 8.3% in 2022-23 to 5.6% in 2025. Daily vaping rates stabilised at 3.6%, while the government also moved to further restrict access to nicotine pouches through unapproved therapeutic import pathways.
Jul.21